The effect of docetaxel on developing oedema in patients with breast cancer: A systematic review

European Journal of Cancer Care

Volumn 25, Issue 2, 2016, Pages 269-279

  Hugenholtz Wamsteker, W ^a,b   Robbeson, C ^a,c   Nijs, J ^a,d,e,f   Hoelen, W ^a   Meeus, Mira ^a,d,g,h  

^a European College for Lymphology and Oncology   (Netherlands)

^b Procare Fysiotherapie and Trainingscentrum   (Netherlands)

^c Fysiotherapie Heuts   (Netherlands)

^d Pain in Motion International Research Group (wwwpaininmotionbe)   (Belgium)

^e VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^f UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^g GHENT UNIVERSITY   (Belgium)

^h UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Chemotherapy; Mamma carcinoma; Risk; Taxotere

Indexed keywords

ANTINEOPLASTIC AGENT; DOCETAXEL; TAXOID;

ADJUVANT CHEMOTHERAPY; BREAST NEOPLASMS; EDEMA; FEMALE; HUMAN; LYMPHEDEMA; MASTECTOMY; POSTOPERATIVE COMPLICATIONS; RISK FACTOR;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; EDEMA; FEMALE; HUMANS; LYMPHEDEMA; MASTECTOMY; POSTOPERATIVE COMPLICATIONS; RISK FACTORS; TAXOIDS;

EID: 84959046918     PISSN: 09615423     EISSN: 13652354     Source Type: Journal    
DOI: 10.1111/ecc.12261     Document Type: Review

References (19)

1. Andersson M., Lidbrink E., Bjerre K., Wist E., Enevoldsen K., Jensen A.B., Karlsson P., Tange U.B., Sorensen P.G., Moller S., Bergh J. & Langkjer S.T. (2011) Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study. Journal of Clinical Oncology 29, 264-271.
2. Baker J., Ajani J., Scotte F., Winther D., Martin M., Aapro M.S. & Von Minckwitz G. (2009) Docetaxel-related side effects and their management. European Journal of Oncology Nursing 13, 49-59.
3. Behar A., Pujade-Lauraine E., Maurel A., Brun M.D., Chauvin F.F., Feuilhade De Chauvin F., Oulid-Aissa D. & Hille D. (1997) The pathophysiological mechanism of fluid retention in advanced cancer patients treated with docetaxel, but not receiving corticosteroid comedication. British Journal of Clinical Pharmacology 43, 653-658.
4. Beuselinck B., Wildiers H., Wynendaele W., Dirix L., Kains J.P. & Paridaens R. (2010) Weekly paclitaxel versus weekly docetaxel in elderly or frail patients with metastatic breast carcinoma: a randomized phase-II study of the Belgian Society of Medical Oncology. Critical Reviews in Oncology 75, 70-77.
5. Ferlay J., Soerjomataram I., Ervik M., Dikshit R., Eser S., Mathers C., Rebelo M., Parkin D.M., Forman D. & Bray F. (2013) GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet] [Online] Lyon, France. Available at: http://globocan.iarc.fr
6. Gasparini G., Pozza F. & Harris A.L. (1993) Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients. Journal of the National Cancer Institute 85, 1206-1219.
7. Iwata H., Nakamura S., Toi M., Shin E., Masuda N., Ohno S., Takatsuka Y., Hisamatsu K., Yamazaki K., Kusama M., Kaise H., Sato Y., Kuroi K., Akiyama F., Tsuda H., Kurosumi M. & Japan Breast Cancer Research, G. (2005) Interim analysis of a phase II trial of cyclophosphamide, epirubicin and 5-fluorouracil (CEF) followed by docetaxel as preoperative chemotherapy for early stage breast carcinoma. Breast Cancer (Tokyo, Japan) 12, 99-103.
8. Jones S.E., Erban J., Overmoyer B., Budd G.T., Hutchins L., Lower E., Laufman L., Sundaram S., Urba W.J., Pritchard K.I., Mennel R., Richards D., Olsen S., Meyers M.L. & Ravdin P.M. (2005) Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. Journal of Clinical Oncology 23, 5542-5551.
9. Jones S.E., Savin M.A., Holmes F.A., O'shaughnessy J.A., Blum J.L., Vukelja S., McIntyre K.J., Pippen J.E., Bordelon J.H., Kirby R., Sandbach J., Hyman W.J., Khandelwal P., Negron A.G., Richards D.A., Anthony S.P., Mennel R.G., Boehm K.A., Meyer W.G. & Asmar L. (2006) Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. Journal of Clinical Oncology 24, 5381-5387.
10. Kouroussis C., Xydakis E., Potamianou A., Giannakakis T., Kakolyris S., Agelaki S., Sara E., Malamos N., Alexopoulos A., Mavroudis D., Samonis G., Papadouris S., Georgoulias V. & Panagos G. (1999) Front-line treatment of metastatic breast cancer with docetaxel and epirubicin: a multicenter dose-escalation study. The Greek Breast Cancer Cooperative Group (GBCCG). Annals of Oncology 10, 547-552.
11. Mitchell P.L., Basser R., Chipman M., Grigg A., Mansfield R., Cebon J., Davis I.D., Appia F. & Green M. (2004) A phase II study of escalated-dose docetaxel with granulocyte colony-stimulating factor support in patients with advanced breast cancer. Annals of Oncology 15, 585-589.
12. Moher D., Liberati A., Tetzlaff J., Altman D.G. & Group P. (2010) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. International Journal of Surgery 8, 336-341.
13. Norman S.A., Localio A.R., Kallan M.J., Weber A.L., Torpey H.A., Potashnik S.L., Miller L.T., Fox K.R., Demichele A. & Solin L.J. (2010) Risk factors for lymphedema after breast cancer treatment. Cancer Epidemiology, Biomarkers and Prevention: A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology 19, 2734-2746.
14. Ohsumi S., Shimozuma K., Ohashi Y., Takeuchi A., Suemasu K., Kuranami M., Ohno S. & Watanabe T. (2012) Subjective and objective assessment of edema during adjuvant chemotherapy for breast cancer using taxane-containing regimens in a randomized controlled trial: the National Surgical Adjuvant Study of Breast Cancer 02. Oncology 82, 131-138.
15. Qin Y.Y., Li H., Guo X.J., Ye X.F., Wei X., Zhou Y.H., Zhang X.J., Wang C., Qian W., Lu J. & He J. (2011) Adjuvant chemotherapy, with or without taxanes, in early or operable breast cancer: a meta-analysis of 19 randomized trials with 30698 patients. PLoS ONE 6, e26946.
16. Roché H., Fumoleau P., Spielmann M., Canon J.L., Delozier T., Serin D., Symann M., Kerbrat P., Soulie P., Eichler F., Viens P., Monnier A., Vindevoghel A., Campone M., Goudier M.J., Bonneterre J., Ferrero J.M., Martin A.L., Geneve J. & Asselain B. (2006) Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. Journal of Clinical Oncology 24, 5664-5671.
17. Salminen E., Bergman M., Huhtala S. & Ekholm E. (1999) Docetaxel: standard recommended dose of 100mg/m(2) is effective but not feasible for some metastatic breast cancer patients heavily pretreated with chemotherapy-A phase II single-center study. Journal of Clinical Oncology 17, 1127.
18. Semb K.A., Aamdal S. & Oian P. (1998) Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment. Journal of Clinical Oncology 16, 3426-3432.
19. Sjöström J., Blomqvist C., Mouridsen H., Pluzanska A., Ottosson-Lonn S., Bengtsson N.O., Ostenstad B., Mjaaland I., Palm-Sjovall M., Wist E., Valvere V., Anderson H. & Bergh J. (1999) Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group. European Journal of Cancer 35, 1194-1201.